Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells

Cancer Gene Ther. 2004 May;11(5):309-16. doi: 10.1038/sj.cgt.7700706.

Abstract

Antiapoptotic genes such as bcl-2 or xIAP may be responsible for resistance to apoptosis induced by cytotoxic drugs. The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. FITC-siRNAs uptake was verified by fluorescence microscopy and downregulation of Bcl-2 or XIAP was confirmed by Western Blotting. Both siRNAs reduced the number of viable cells and increased cellular apoptosis. Treatment with siRNAs followed by treatment with etoposide or doxorubicin further reduced the number of viable cells, when compared to either of the treatments alone. Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Cell Line, Tumor
  • Down-Regulation / genetics*
  • Doxorubicin / pharmacology
  • Etoposide / pharmacology
  • Female
  • Humans
  • Proteins / genetics*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • RNA, Small Interfering / genetics*
  • Transfection
  • X-Linked Inhibitor of Apoptosis Protein

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Phytogenic
  • Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Small Interfering
  • X-Linked Inhibitor of Apoptosis Protein
  • XIAP protein, human
  • Etoposide
  • Doxorubicin